Investments

RMI Partners’s investment focus is novel biopharmaceutical products, medical technologies and diagnostic tools that can help extend human life and make it healthier and more productive. We firmly believe in the future of advanced technology and strive to support innovative projects that are success-oriented and provide adequate profits to the investors.

Our main investment criteria:

      * Novel breakthrough technology

                                                                    * Experienced team

                                                                    * Significant medical problem

                                                                    * Tangible commercial prospects in the market

News

  • 25 September 2018

    Syndax Announces Changes to its Board of Directors

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of  Jennifer Jarrett  and  William Meury to its Board of Directors, effective today.  Ms. Jarrett and Mr. Meury will succeed  Luke Evnin , Ph.D. and  Henry Chen , who resigned as active members of the Syndax Board of Directors, effective today.

  • 25 September 2018

    Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression.